NCT02658084View on ClinicalTrials.gov

Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 12, 2017

Primary Completion Date

October 11, 2018

Study Completion Date

October 11, 2018

Conditions
Breast CancerMetastatic Breast Cancer
Interventions
DRUG

Vinorelbine

Administered as an intravenous infusion on Day 1 and Day 8 of every 21-day cycle.

DRUG

Trastuzumab Emtansine

Administered as an intravenous infusion on Day 1 of every 21-day cycle.

Trial Locations (1)

33136

University of Miami, Miami

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Miami

OTHER